Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;16(3):237-43.
doi: 10.1093/icvts/ivs465. Epub 2012 Nov 21.

Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?

Joerg Lindenmann  1 , Veronika Matzi, Nicole Neuboeck, Udo Anegg, Alfred Maier, Josef Smolle, Freyja Maria Smolle-Juettner
Affiliations

Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?

Joerg Lindenmann et al. Interact Cardiovasc Thorac Surg. 2013 Mar.

Abstract

Objectives: Malignant pleural mesothelioma (MPM) remains an aggressive thoracic malignancy associated with poor prognosis. There is no standard treatment regimen, and particularly, the impact of radical surgery remains controversial. The main goal of our retrospective single-centre study was to evaluate the surgical and non-surgical treatment modalities applied at our division regarding their effect on the patient's survival.

Methods: During the last decade, 82 patients with histologically confirmed MPM were treated at our division. The complete clinical records of 61 patients were eligible for statistical evaluation.

Results: There were 14 women (23%) and 47 men (77%) with a mean age of 63.7 years. Epitheloid subtype was found in 48 patients (78.7%), sarcomatoid in 3 (4.9%) and biphasic in 10 (16%). Surgery as the first treatment modality was performed in 44 patients (72.1%). Pleurectomy/decortication was done in 28 cases (45.9%), extended pleurectomy/decortication was performed in 13 (21.3%) and extrapleural pneumonectomy in 3 (4.9%). Additional intraoperative photodynamic therapy was administered in 20 patients, 34 underwent chemotherapy (55.7%) and 12 had radiotherapy (19.7%). Mean survival time for the collective was 18.3 months. Five-year survival was 17% in the epitheloid histology group, where patients treated with chemotherapy alone yielded a significant increase in survival (P = 0.049), and those with other subtypes survived for a maximum of 20.6 months.

Conclusions: Chemotherapy and pleurectomy/decortication can extend the survival time of patients with MPM remarkably. The adequate treatment options have to be tailored to the specific particular needs of each patient considering histological subtype, tumour stage and patient's individual functional assessment as well as comorbidity.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Kaplan–Meier curve showing the median survival of all 61 patients with malignant pleural mesothelioma regarding histologic tumour grading (P = 0.019).
Figure 2:
Figure 2:
Kaplan–Meier curve showing the median survival of all 61 patients with malignant pleural mesothelioma regarding histologic subtype (P = 0.02).
Figure 3:
Figure 3:
Kaplan–Meier curve showing the median survival of all 61 patients with malignant pleural mesothelioma regarding administration of systemic chemotherapy (P = 0.049).
See this image and copyright information in PMC

References

    1. Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:163–72. - PMC - PubMed
    1. Greillier L, Marco S, Barlesi F. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies. Anticancer Drugs. 2011;22:199–205. doi:10.1097/CAD.0b013e328341ccdd. - DOI - PubMed
    1. Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, et al. International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6:1304–12. doi:10.1097/JTO.0b013e3182208e3f. - DOI - PubMed
    1. Lindenmann J, Matzi V, Neubock N, Maier A, Smolle-Juttner FM. The clinical impact of photodynamic therapy in thoracic surgery. Eur Surg. 2010;42:220–8. doi:10.1007/s10353-010-0559-5. - DOI
    1. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–65. doi:10.1097/JTO.0b013e31815608d9. - DOI - PubMed

MeSH terms